Company intelligence / Profile preview

AmpTec

Hamburg, Hamburg, Germany

Ownership: Private
Employees: ~40
Development stage: Other

Overview

AmpTec is a commercial mRNA-focused CDMO providing cGMP and research-grade synthetic mRNAs and long RNAs/DNAs for use as drug substances, APIs and reference materials in vaccines, therapeutics and in vitro diagnostics; it does not develop its own clinical pipeline but supports clients' preclinical to clinical programs including up to phase 1 trials.[1][2][3][5]

Modalities: mRNA-based drugsRNA therapySynthetic oligonucleotide
Industry: Contract Manufacturing Organization

Partnerships

MilliporeSigma (integrated mRNA + lipid offering within Merck KGaA life science business)[5][7]

Beyond the preview

Go deeper on AmpTec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmpTec.

Explore the full profile